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The analysis of the ethical discourse on Individualized
Medicine (IM) within the context of PPPM, shows that
the most extensively studied areas are (still) relatively far
away from a practical implementation. The discussion of
IM as an engine of a “dictatorship of prevention”, in
which IM is placed in the context of the ethical accept-
ability of mandatory screening tests or the rejection of
the principle of solidarity under the banner of personal
health responsibility, can be understood as a prime
example. However, such discussions are situated within
the range of a purely “hypothetical ethics”, since the
extensive medical knowledge and applications they are
based on merely exist in the anticipation of potential
successes, rather than the outcome of the real research
context of IM, which - particularly in the area of complex
diseases - does not go far beyond the level of rather trivial
recommendations for a fundamentally healthy lifestyle.
On the other hand, if one focuses on the reality in the
field of IM research, it becomes evident that there are
promising approaches mainly in two areas, both of which
are not very promising for “hypothetical ethics": The
fields of biomarker-based prediction of the course of a
disease (e.g. in oncology) and the biomarker-based pre-
diction of the success of drug and non-drug interven-
tions. The progress in research in Germany’s largest joint
project for IM, GANI_MED – Greifswald Approach to
Individualized Medicine – exactly points in that direc-
tion: The promising studies within GANI_MED refer to
limited and clearly defined questions. The endocrinologi-
cally based prediction of the course of a metabolic syn-
drome as well as the use of biomarkers for the prediction
of treatment response for immunoadsorption in dilated
cardiomyopathy are to be named here as respective
examples. Obviously, both examples can be understood
as examples for the ethical problems of marginal utility,
but they certainly give no reason for an alarmist self-
promotion of bioethics. Even if one concedes that the
alarm calls off bioethics have been provoked through
excessive promise of healing and output of IM-propaga-
tors and stakeholders in medicine and human biology, it
has to be noted that the current status of research raises
a very differentiated and, in parts decidedly, clear-cut
record: The biomarker-based IM is - according to the
thesis of the authors - certainly not the new paradigm of
medicine, but a research approach, which may contribute
progress in very limited areas in medical care.
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